A video on Investment Pitch Media describes the pending acquisition of the naltrexone therapeutic by Love Pharma and is supported by reports that naltrexone has demonstrated a long and promising COVID filing.Canadian Business Journal

VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) — LOVE Pharma (CSE) has signed a non-binding letter of intent to acquire 100% of Naltrexone Therapeutics on Oct. 11, 2022. :LUV) (FSE:G1Q0) reports recent developments in naltrexone. Long COVID application.

Media snippets accompanying this announcement are available by clicking the image or link below.

For more information, watch the InvestmentPitch Media video that provides additional information about this news and the company. You can watch the video at “”.investment pitch“When”Youtube”. If these links are not enabled, please visit the following URLs: www.InvestmentPitch.com Type “Love Pharma” in the search box.

The pending acquisition of Naltrexone Therapeutics brings significant IP related to the transdermal delivery of FDA-approved naltrexone. Naltrexone is an opioid antagonist used primarily to manage alcohol and opioid use disorders by reducing the cravings and euphoria associated with substance abuse disorders. The addressable drug addiction treatment market is projected to exceed US$31 billion by 2027.

As Reuters reported this week, at least four clinical trials are planned to test naltrexone in hundreds of COVID patients after several lengthy COVID pilot studies. Additionally, it was reported to be on the shortlist of treatments to be tested in the US National Institutes of Health’s $1 billion RECOVER initiative. This aims to uncover the root cause and find a cure for the long COVID Reuters report not only treats symptoms caused by COVID damage to organs, but low doses of naltrexone reported that it may reverse some of the symptoms that actually cause the underlying medical condition.

Naltrexone, which also has anti-inflammatory properties, has been used in low doses for years to treat conditions such as fibromyalgia, Crohn’s disease, and multiple sclerosis. It is available in 50mg format from generic drug manufacturers. This is 10 times higher than the low doses considered for long-term treatment of COVID, requiring low-dose prescriptions, limiting access and availability.

Transdermal delivery of naltrexone is expected to provide safe and consistent dosing, reduce gastrointestinal-related side effects, and improve the overall patient experience. Although more research is needed, Naltrexone Therapeutics’ transdermal delivery IP may provide a patient-friendly, low-dose delivery solution that is readily available to patients. Most importantly, transdermal delivery of naltrexone may eliminate or reduce the side effects of current drugs such as nausea that may limit the growth of the existing naltrexone market.

Transdermal formulations of drugs can be incorporated into patches that are applied to the patient’s skin surface, thereby providing a consistent rate of absorption over the prescribed prescribed time. As reported, the transdermal delivery of naltrexone can provide plasma concentrations of the drug at a given rate for a given period of time, with great promise for early application in the treatment of his long-term COVID. is expected.

As of October 20, the World Health Organization has confirmed 623 million COVID cases and 6.5 million deaths. Also, according to a National Library of Medicine report, 37.7% of his COVID patients experienced symptoms beyond 12 weeks after infection, leading to a significant market need for treatment.

At this time, LOVE Pharma makes no explicit or implied claims that its products have the ability to eliminate, cure or contain Covid-19.

Focused on the global sexual health and wellness market, Love Pharma was founded in 2020 with the goal of bringing to market innovative products that enhance sexual health and wellness while improving quality of life. It’s our mission. Love Pharma holds exclusive licenses to manufacture, package, market and distribute patented therapeutics and pharmaceuticals in Europe, the United Kingdom and North America.

The stock is currently trading at $0.015. For more information, please visit the company’s website. www.love-pharma.complease contact Zach Stadnyk, CEO, by phone at 604-343-2977 or by email. [email protected].

Disclaimer

The information in this Investmentpitch Media Ltd video is for viewer information. Love Pharma paid him no more than $2,000 in cash to produce the current news release in video format. Company information is based on publicly available information. Information provided by Investmentpitch Media Ltd. through its media services shall not be construed as a recommendation, proposal or offer to buy or sell securities, and is provided solely as an information media service. Investmentpitch Media Ltd makes no warranties or promises as to the accuracy or completeness of this information. All due diligence must be done by the viewer or their financial advisor. Investing in securities is speculative and involves risk.

About Investment Pitch Media

InvestmentPitch Media harnesses the power of video, combined with its wide distribution, to put your company’s story ahead of thousands seeking recognition and funding from the financial industry. The company specializes in producing short videos based on important news releases, research reports and other content of interest to investors.

CBJ Newsmaker